Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.75 USD
+0.17 (6.59%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.73 -0.02 (-0.73%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELDN 2.75 +0.17(6.59%)
Will ELDN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELDN
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ELDN
Eledon Pharmaceuticals files to sell 21.1M shares for holders
Eledon Pharmaceuticals files to sell 21.1M shares of common stock for holders
12 Health Care Stocks Moving In Friday's After-Market Session
LIDR, ELDN and IVP among pre-market losers
Eledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy Rating